Abstract Number: 492 • 2012 ACR/ARHP Annual Meeting
Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
Background/Purpose: There are currently five anti-TNF agents that have been approved for various autoimmune illnesses. There is no convincing evidence that any one of these…Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…Abstract Number: 1705 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) and is defined by the ASAS criteria.1 It is characterized by bone…Abstract Number: 1186 • 2012 ACR/ARHP Annual Meeting
A Single Nucleotide Polymorphism of Tumor Necrosis Factor Receptor-Associated Factor 1 Predicts Clinical Response to Anti-Tumor Necrosis Factor Treatments in Japanese Patients with Rheumatoid Arthritis
Background/Purpose: Recent genome-wide association studies have disclosed several single nucleotide polymorphisms (SNPs) associated with rheumatoid arthritis (RA) susceptibility. Among them, it is reported that the…Abstract Number: 498 • 2012 ACR/ARHP Annual Meeting
LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling
Background/Purpose: We previously reported increased expression of cell membrane RANKL in PBMC of patients with active rheumathoid arthritis (RA) which was down-regulated by anti TNF-α…Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…Abstract Number: 1643 • 2012 ACR/ARHP Annual Meeting
Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Background/Purpose: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF approved in the US for the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA). Pre-clinical…Abstract Number: 1145 • 2012 ACR/ARHP Annual Meeting
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologic therapy, although the majority remain unlicensed for children. Until…Abstract Number: 501 • 2012 ACR/ARHP Annual Meeting
TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
Background/Purpose: Randomized clinical trials in RA have until recently focused on patients (pts) with high disease activity, but the majority of pts in the clinic…Abstract Number: 2613 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Background/Purpose: Certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has shown efficacy in reducing signs and symptoms of psoriatic arthritis (PsA).1 RAPID-PsA (NCT01087788) is the first…Abstract Number: 1626 • 2012 ACR/ARHP Annual Meeting
Frequent Conversion of Tuberculosis Screening Tests During Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatic Diseases
Background/Purpose: The most recent ACR Recommendations suggest annual screening for latent tuberculosis (TB) with standard tuberculin skin test (TST) or the newer interferon-gamma release assays…Abstract Number: 1011 • 2012 ACR/ARHP Annual Meeting
Structural Damage Is Reduced by Early Achievement of Clinical Remission
Background/Purpose: The importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent structural damage is established.1 The objective of this…Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…Abstract Number: 2331 • 2012 ACR/ARHP Annual Meeting
The Effects of Anti–Tumor Necrosis Factor Agents On the Expansion of T Helper-Type 17 Cells Driven by Lipopolysaccharide-Stimulated Monocytes
Background/Purpose: T helper-type 17 (Th17) cells are proinflammatory CD4+ cells characterized by the production of Interleukin-17 (IL-17).There is evidence that IL-17 and other cytokines which…Abstract Number: 1560 • 2012 ACR/ARHP Annual Meeting
What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review
Background/Purpose: In the early stages of Rheumatoid Arthritis (RA), adherence to the prescribed treatment is important to prevent irreversible joint damage. However, medication adherence rates…
ACR Meeting Abstracts